[No authors listed] A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. The I.S.A.M. Study Group. N Engl J Med. 1986 Jun 5, 314(23), 1465-1471. [PMID]: 2871492.

Schroder R, Neuhaus KL, Leizorovicz A, Linderer T, Tebbe U. A prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): long-term mortality and morbidity. J Am Coll Cardiol. 1987 Jan, 9(1), 197-203. [PMID]: 3540072.

Schroder R, Neuhaus KL, Linderer T, Bruggemann T, Tebbe U, Wegscheider K. Impact of late coronary artery reperfusion on left ventricular function one month after acute myocardial infarction (results from the ISAM study). Am J Cardiol. 1989 Oct 15, 64(14), 878-884. [PMID]: 2801555.

Schroder R, Linderer T, Bruggemann T, Neuhaus KL, Tebbe U, Wegscheider K. Controversial indications. Rationale for thrombolysis: later than 4-6 h from symptom onset, and in patients with smaller myocardial infarctions. The ISAM Study Group. Eur Heart J. 1990 Aug, 11 Suppl F, 19-28. [PMID]: 2226538.